SCHEMBL6660057

SCHEMBL6660057

BrCc1ccc2c(c1)CCc1cc(CBr)ccc1-2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.39
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
SRD5A1 P18405 3/20 0.36
SRD5A2 P31213 3/20 0.36
TSHR P16473 3/20 0.35
ALDH1A1 P00352 2/20 0.35
ATM Q13315 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PARP11 Q9NR21 1/20 0.35
TRPA1 O75762 1/20 0.35
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
CYP26A1 O43174 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7540168 0.86 TSHR (0.46) ESR1ESR2SRD5A2TSHRALDH1A1
SCHEMBL4814687 0.86 CASP1 (0.53) AKR1B1CASP1CASP7HSD17B10MAOA
SCHEMBL31468782 0.83 TRPA1 (0.36) ESR1ESR2TSHRALDH1A1TRPA1
SCHEMBL29780668 0.77 TSHR (0.59) SRD5A2TSHRALDH1A1ATMNPSR1
SCHEMBL7974044 0.77 TSHR (0.59) SRD5A2TSHRALDH1A1ATMNPSR1
SCHEMBL7127913 0.76 AKR1B1 (0.42) AKR1B1SRD5A1SRD5A2TSHRPARP11
SCHEMBL3284644 0.76 TSHR (0.42) TSHRALDH1A1HSD17B10
SCHEMBL11620189 0.76 AKR1B1 (0.39) AKR1B1SRD5A1SRD5A2TSHRALDH1A1
SCHEMBL3279449 0.74 RXRB (0.42) TSHRALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3453711 0.74 SRD5A1 (0.45) SRD5A1SRD5A2TSHRALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029332-B2 Cross-linked peptides and proteins, methods of making same, and uses thereof THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2015-05-12 US disclosed
US-9029332-B2 Cross-linked peptides and proteins, methods of making same, and uses thereof THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2015-05-12 US disclosed
US-20140057857-A1 Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2014-02-27 US disclosed
US-20140057857-A1 Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2014-02-27 US disclosed
WO-2012083078-A2 CROOS-LINKED PEPTIDES AND PROTEINS, METHODS OF MAKING SAME, AND USES THEREOF THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2012-06-21 WO disclosed
WO-2004003044-A2 DYNAMERS: POLYMERIC MATERIALS EXHIBITING REVERSIBLE FORMATION AND COMPONENT EXCHANGE LEHN JEAN-MARIE (FR) 2004-01-08 WO disclosed
US-4096154-A FORMING A SULFONIUM SALT BY REACTION OF A HALOGEN AS ESTER WITH AN ORGANIC SULFIDE CIBA-GEIGY CORPORATION (US) 1978-06-20 US disclosed
US-4016203-A Process for the manufacture of compounds containing vinyl groups CIBA-GEIGY CORPORATION (US) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057857-A1 Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof TIMCC, LCP1, DNPEP AKR1B1 4362/4885ESR1 3528/4885ESR2 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.